Supplements and Your Heart Medications

Where supplements meet medications. The interactions that matter — and the limits of any list.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not to replace medical care.

Safety note: This article describes a selection of the better-documented interactions, not a complete catalog; many supplements and combinations are not covered, and the absence of a supplement here does not mean it is free of interactions — only that it is not discussed, and no general article can substitute for a pharmacist or prescriber reviewing your specific list. Several supplements in this article carry documented interaction risks. Nattokinase has clot-dissolving activity that adds to the bleeding risk of anticoagulant or antiplatelet drugs. Alpha-lipoic acid can lower blood glucose, which matters for people on diabetes medications. High-dose cassia cinnamon contains coumarin, which is hepatotoxic at sustained high intake. L-carnitine raises a gut-derived metabolite, TMAO, that is associated with cardiovascular risk in observational studies. The single most protective practice, for these and for any supplement not named here, is disclosure: every supplement, to every prescriber and pharmacist, at every visit.

In brief: Supplements interact with cardiovascular medications through the same biological systems those medications act on — bleeding pathways, liver metabolism, potassium handling, blood pressure, and blood glucose — so the category of interaction is usually predictable even when the magnitude is not. A small number of combinations consistently cause harm and deserve particular attention: St. John’s Wort with most cardiovascular drugs; vitamin K supplements with warfarin; potassium supplements with ACE inhibitors, ARBs, or potassium-sparing diuretics, especially in kidney disease; berberine with statins, warfarin, or DOACs; and red yeast rice taken with a prescription statin. (1,3,4) This article describes selected, well-documented interactions and is not a complete list; the absence of a supplement here does not mean it is free of interactions. The single most protective practice is disclosure — every supplement, to every prescriber and pharmacist, at every visit — because the dangerous interactions are usually the ones no one in the care team knew were possible. Most interactions are manageable once known; the unmanaged ones are where harm occurs.

Where the Interactions Stand

Interactions covered here differ in how well established they are, and that difference is worth keeping in view. A handful are well documented — supported by controlled studies, large observational data, or a well-characterized mechanism with clear clinical consequences — and these deserve particular attention and explicit discussion with a prescriber before combining. A larger group is plausible and reported, resting on case reports or a known mechanism with thinner clinical evidence, where disclosure and monitoring are the appropriate response. A third group is theoretical, where a mechanism suggests a possible interaction but clinical evidence is limited or absent, and disclosure is reasonable while urgency is lower. How well established an interaction is reflects how confident anyone can be that it matters — not how dangerous it is for a given person, since a well-documented interaction in a low-risk patient can matter less than a thinly-evidenced one in a frail patient on five medications. As the safety note above states, what follows is a selection, not the full universe of possible interactions.

Best-established (warrant discussion before combining): St. John’s Wort with most cardiovascular drugs (1); vitamin K supplements with warfarin; potassium supplements with ACE inhibitors, ARBs, or potassium-sparing diuretics, especially in kidney disease (2); berberine with statins, warfarin, or DOACs (3); red yeast rice combined with a prescription statin (4).

Plausible and reported (disclose and monitor): garlic supplements (not culinary amounts) with warfarin or antiplatelets (5); ginkgo with anticoagulants or antiplatelets (6); high-dose vitamin E with anticoagulants (7); nattokinase with anticoagulants or antiplatelets (8); beetroot or dietary-nitrate supplements with nitrate medications (15); berberine with diabetes medications; CoQ10 with warfarin (10); curcumin with anticoagulants.

Theoretical or weakly supported (disclose; lower urgency): alpha-lipoic acid, cinnamon, or chromium with diabetes medications; L-citrulline or L-arginine with antihypertensives (16); higher-dose magnesium with antihypertensives (14).

Find Your Situation

This finder lists the situations this article covers. It is not exhaustive; other supplements you take may carry interactions not shown here, which is why disclosure to your prescriber and pharmacist remains the essential step.

Why This Article Exists

Supplements interact with cardiovascular medications through the same biological systems those medications depend on. They are pharmacology. A supplement that increases bleeding risk on warfarin is not harmless because it comes from a plant. A supplement that lowers a medication’s blood level is not safe because it has been used in traditional medicine for centuries. The label on the bottle does not change the chemistry in the bloodstream.

Most patients do not routinely disclose supplements to their doctors, and clinicians do not always systematically ask. Supplements are categorized as food products and excluded from routine medication review, and the word “natural” implies a safety the pharmacology does not support. The result is that important interactions can occur without anyone in the care team knowing they are possible.

Two principles frame everything below.

The dose makes the interaction. Many supplement–drug interactions are dose-dependent. Culinary garlic in a meal is not a concentrated garlic-extract capsule. Dietary potassium from a banana is not a 99 mg potassium tablet. Dietary vitamin K from spinach is not a vitamin K2 supplement. Most catastrophic interactions involve concentrated supplemental forms, not food.

Risk is not evenly distributed. It rises with age, with kidney disease, with the number of medications a person takes, and with frailty. A 75-year-old on five cardiovascular medications with impaired kidney function is in a different category than a healthy 45-year-old on no prescriptions. The smaller number of high-stakes combinations matters most in the higher-risk group, and the goal here is not to make anyone afraid of supplements — it is to make those few combinations visible to the people taking them.

Bleeding Risk: The Highest-Stakes Category

Any drug that affects blood clotting — an anticoagulant such as warfarin or a DOAC, or an antiplatelet such as aspirin or clopidogrel — sits among cardiovascular medicine’s most consequential classes. The margin between therapeutic and dangerous is narrow, and interactions in either direction matter.

Warfarin: A Category Apart

Warfarin warrants its own section because its interaction profile is broader, its therapeutic window is narrower, and its monitoring provides a measurable signal that interactions are occurring. The INR — International Normalized Ratio — measures how long blood takes to clot relative to a standard: higher INR means more anticoagulation and more bleeding risk, lower INR means less anticoagulation and more clotting risk. Warfarin is dosed to a target INR (commonly 2–3 for atrial fibrillation, higher for some mechanical valves), and small shifts in either direction can be clinically significant. Warfarin works by blocking vitamin K’s role in activating clotting factors, so anything that changes vitamin K availability or warfarin metabolism will move the INR.

Vitamin K supplements — a direct, well-established interaction. Vitamin K directly opposes warfarin. Taking vitamin K2 supplements (marketed for bone or arterial health, covered in Article 14) while on warfarin reduces anticoagulation and can allow dangerous clots to form. This is basic pharmacology, not a theoretical concern, and combining the two is something to undertake only with explicit medical coordination and INR monitoring, if at all.

Dietary vitamin K from food is a different matter. The aim is not to avoid leafy greens but to keep intake consistent. Large swings — dramatically increasing or decreasing spinach, kale, broccoli, or Brussels sprouts — destabilize warfarin control. Consistency matters more than avoidance.

St. John’s Wort with warfarin — well established. St. John’s Wort accelerates warfarin’s breakdown, reducing INR and anticoagulation through a well-characterized mechanism driven by hyperforin’s induction of drug-metabolizing enzymes. (1) The Swedish Medical Products Agency reported seven cases of stable warfarin patients whose INR fell after starting St. John’s Wort and recovered after it was stopped; no thromboembolic events occurred in that series, but the INR drops were clinically significant and can develop within days. (9) This combination is one to use only with medical coordination.

CoQ10 with warfarin — plausible, case-report level. CoQ10 is structurally similar to vitamin K. Case reports describe reduced INR after CoQ10 is started, suggesting interference with vitamin K–dependent clotting-factor activation; controlled studies have been inconsistent. (10) The signal is real enough that starting CoQ10 in a warfarin patient warrants INR monitoring and disclosure.

Garlic supplements with warfarin — plausible, case-report level. Garlic contains compounds that inhibit platelet aggregation, and case reports describe elevated INR and bleeding when garlic supplements are combined with warfarin. (5) The evidence is case-report level rather than controlled-trial, but the mechanism is plausible and warfarin destabilization carries serious consequences. Culinary amounts in food are not a meaningful concern; concentrated supplements are different.

The unifying point: warfarin is unusually sensitive to both vitamin K fluctuations and changes in liver metabolism, so supplements affecting either pathway can shift the INR — sometimes substantially, sometimes within days. Disclosing every supplement to the team managing anticoagulation, and requesting an INR check when starting or stopping anything, is the practice that catches these early.

Antiplatelet Drugs: Aspirin, Clopidogrel, and Others

Antiplatelet therapy after a coronary stent, heart attack, or stroke is often non-negotiable, and dual antiplatelet therapy — aspirin plus clopidogrel, prasugrel, or ticagrelor — is common in the first year after an acute coronary event. Adding supplements with antiplatelet properties creates additive bleeding risk without adding cardiovascular protection.

Ginkgo biloba — plausible and reported. Ginkgo antagonizes platelet-activating factor. A systematic review of case reports identified fifteen bleeding events temporally associated with ginkgo, including eight episodes of intracranial bleeding, though most involved other bleeding risk factors as well. (6) Given the seriousness of the reported events, ginkgo is generally one to avoid in patients on antithrombotic therapy — a decision best made with the prescriber.

Nattokinase — a mechanism-based concern. Nattokinase is a clot-dissolving enzyme that breaks down fibrin, the structural protein of clots. (8) Adding it to anticoagulant or antiplatelet therapy creates additive antithrombotic exposure with no established cardiovascular outcome benefit to justify it. This is the clearest case in the supplement field where the therapeutic mechanism is itself the safety concern, and the combination warrants explicit medical guidance before use.

Standard fish oil versus prescription icosapent ethyl — context-specific. Standard over-the-counter fish oil at 1–3 grams daily has not been shown to cause clinically significant bleeding. A 2024 meta-analysis of randomized omega-3 trials including more than 120,000 participants found no overall increase in bleeding events, with only high-dose purified EPA showing a small signal of minimal clinical impact. (11) By contrast, prescription icosapent ethyl at 4 grams daily in the REDUCE-IT trial showed a higher overall bleeding rate (11.8% vs 9.9%) and a borderline increase in serious bleeding (2.7% vs 2.1%, P=0.06), with no fatal bleeding events in either group. (12) That is a prescription-drug effect at high dose, not a standard fish-oil effect — the bleeding signal commonly attributed to over-the-counter fish oil is weaker in the trial data than in clinical lore.

High-dose vitamin E — plausible, inconsistent evidence. Vitamin E inhibits platelet aggregation in vitro and may potentiate anticoagulants, though controlled-trial evidence is inconsistent. (7) Above 400 IU daily, the signal is enough to warrant disclosure to a prescriber managing anticoagulation; at typical doses of 100–200 IU, the clinical significance is less clear.

DOACs: A Different Profile from Warfarin

Direct oral anticoagulants — apixaban, rivaroxaban, dabigatran, edoxaban — do not interact with vitamin K, one of their advantages over warfarin. They are, however, metabolized through CYP3A4 and P-glycoprotein, which makes them susceptible to supplements that affect those pathways. CYP3A4 is the single most important drug-metabolizing enzyme, handling roughly half of all prescription medications; P-glycoprotein is a transporter that pumps drugs out of cells, limiting absorption. Supplements that induce these pathways — St. John’s Wort — reduce DOAC blood levels and anticoagulant effect, raising clot risk; supplements that inhibit them — berberine — raise DOAC levels and bleeding risk. (1,3) Berberine with a DOAC warrants the same caution as berberine with a statin: a well-established concern that calls for prescriber discussion before combining. (3)

Potassium and Hyperkalemia: A Frequently Missed Interaction

Hyperkalemia — dangerously elevated blood potassium — alters cardiac conduction in ways that can precipitate ventricular arrhythmias, and severe cases can be life-threatening. The patients most at risk are often the least aware of it: people on ACE inhibitors, ARBs, or spironolactone for heart failure or hypertension who add potassium supplements or potassium-based salt substitutes believing they are making a healthy choice.

The mechanism. The kidneys normally excrete excess potassium efficiently, and several cardiovascular medications impair this. ACE inhibitors (lisinopril, ramipril) reduce potassium excretion by blunting aldosterone’s effect on renal tubular cells. ARBs (losartan, valsartan) block the same pathway by a different route. Potassium-sparing diuretics — spironolactone and eplerenone, common in heart failure and resistant hypertension — directly prevent renal potassium excretion. When a patient on these medications adds potassium from tablets, potassium-based salt substitutes (“lite salt”), or high-potassium protein powders, potassium can accumulate to dangerous levels.

Why kidney disease amplifies the risk. The kidneys are the main route of potassium excretion. In chronic kidney disease — common in cardiovascular patients, especially those with diabetes or longstanding hypertension — that excretion is already impaired. Adding medications that further reduce it, then adding supplemental potassium, creates compounding risk that can produce severe hyperkalemia quickly. Patients with chronic kidney disease on an ACE inhibitor or ARB are the highest-risk group for supplement-induced hyperkalemia, and any change in dietary or supplemental potassium in this group calls for explicit medical management.

The clinical picture. Mild hyperkalemia may cause no symptoms. More severe elevations can cause weakness, palpitations, dangerous rhythm abnormalities, and, at the extreme, cardiac arrest. The transition from asymptomatic to life-threatening can occur without clear warning, which is what makes this interaction dangerous.

What the evidence does — and does not — say. Increased dietary potassium lowers blood pressure in people with hypertension and is associated with a lower risk of stroke, with no adverse effect on kidney function in people whose renal handling of potassium is intact. (2) That benefit is why potassium is recommended in many dietary patterns. The danger is specific: concentrated supplemental potassium, combined with medications that impair excretion, in people whose kidneys cannot compensate. Dietary potassium from whole fruits, vegetables, and legumes — absorbed gradually across a meal — is handled differently from concentrated supplements and is generally safe for people with normal kidney function on these medications. (2) Those with significant chronic kidney disease, however, should discuss even dietary potassium with their nephrologist or cardiologist, and potassium supplements or salt substitutes are a combination to undertake only with explicit discussion and serum-potassium monitoring. Cardiology guidelines reflect this by mandating potassium monitoring whenever spironolactone is added to an ACE inhibitor or ARB.

Liver Metabolism: How Supplements Change Drug Levels

Most important supplement–drug interactions happen at the level of metabolism. The liver processes most medications through cytochrome P450 (CYP450) enzymes, which break drugs down for elimination. If a supplement speeds that machinery up, drug levels fall and the medication works less well; if it slows the machinery down, drug levels rise and side effects or toxicity become more likely. The direction sets the type of risk; the magnitude sets the consequence.

St. John’s Wort: The Broadest Interactor

St. John’s Wort (Hypericum perforatum) speeds up multiple major drug-processing pathways in the liver and intestine at once, which is why its interaction profile is broader than virtually any other supplement. (1) The effect is driven largely by hyperforin, and its magnitude correlates with the hyperforin content of the specific preparation — high-hyperforin extracts induce CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein, while low-hyperforin extracts show little clinically relevant induction. (1)

Among cardiovascular medications, this matters for statins metabolized by CYP3A4 (simvastatin, atorvastatin, lovastatin), where St. John’s Wort can reduce blood levels and diminish LDL-lowering; for warfarin, where faster clearance lowers the INR (1,9); and for DOACs, calcium channel blockers, and antiarrhythmics processed through CYP3A4, where it reduces drug levels and effect. The specific drugs are illustrations of one underlying mechanism, not separate problems to memorize. The clinical message is consistent: St. John’s Wort should be combined with cardiovascular drugs only with explicit prescriber involvement and monitoring, and for someone taking it for depression or anxiety, alternatives with lower interaction potential exist and are worth raising with the prescriber.

Berberine: A Broad Inhibitor of Drug Metabolism

Where St. John’s Wort speeds the machinery up, berberine slows it down — opposite direction, opposite consequence, different patients at risk. In a controlled human study, berberine 300 mg three times daily for two weeks reduced CYP2D6 activity roughly ninefold, doubled a CYP2C9 substrate ratio, and increased exposure to the CYP3A4 substrate midazolam by about 40%. (3) In plain terms, berberine can substantially raise the blood levels of medications cleared by these enzymes, including several cardiovascular drugs.

For statins, most of which are CYP3A4 substrates, berberine raises levels of simvastatin, lovastatin, and atorvastatin, increasing myopathy risk without any added LDL benefit; pravastatin and rosuvastatin use different pathways and are less affected. A patient who starts berberine while on simvastatin 40 mg may effectively receive higher exposure than the prescriber intended, with no change in the prescription. For warfarin, CYP2C9 inhibition may raise levels and INR — the opposite direction from St. John’s Wort, meaning berberine may over-anticoagulate where St. John’s Wort under-anticoagulates. For DOACs, P-glycoprotein and CYP3A4 inhibition may raise levels. For cardiovascular patients on statins, warfarin, or DOACs, berberine is a well-established interaction that warrants explicit prescriber discussion before use. The full berberine evidence is covered in Article 13.

Red Yeast Rice with Prescription Statins

Red yeast rice naturally contains monacolin K, which is chemically identical to lovastatin. (4) Taking it while on a prescription statin is not, strictly, a drug interaction — it is taking two statins at once, producing greater statin exposure than intended, with increased myopathy risk and without the dose precision of pharmaceutical manufacturing. Independent testing of 12 commercial red yeast rice products found monacolin K content ranging from 0.10 to 10.09 mg per capsule — roughly a 100-fold range across products labeled identically — and elevated levels of citrinin, a nephrotoxic mold byproduct, in one-third of the products. (4) A patient may take the “same” supplement for years while receiving very different statin exposures from one bottle to the next. Added to a prescription statin, red yeast rice provides no complementary benefit, only variable, unregulated statin exposure on top of an existing dose.

Grapefruit: A Food That Behaves Like a Supplement

Grapefruit and grapefruit juice irreversibly inhibit CYP3A4 in intestinal cells, slowing metabolism and raising blood levels of affected drugs — the same mechanism as supplement–drug CYP3A4 interactions. (13) Among cardiovascular medications it affects simvastatin, atorvastatin, and lovastatin (but not pravastatin, rosuvastatin, or fluvastatin); calcium channel blockers such as felodipine, nifedipine, and amlodipine, where elevated levels can cause excessive blood-pressure lowering and ankle swelling; and the antiarrhythmics amiodarone and dronedarone, which have narrow therapeutic windows. (13) Because the inhibition involves enzyme degradation rather than temporary blocking, a single 200–250 mL glass can affect drug levels for 24–72 hours, and patients on simvastatin or lovastatin are typically advised to avoid grapefruit. Anyone on these medications who has not been counseled about grapefruit can raise it with a pharmacist. (13)

Blood Pressure: Additive Effects

Antihypertensive medications lower blood pressure by design, and adding supplements with blood-pressure-lowering effects creates additive reduction that is usually manageable but can cause symptomatic hypotension — particularly in older adults, in patients already well-controlled, and in those who are volume-depleted. For context, the supplement effects below are real but modest, typically a few mmHg, against the 10–15+ mmHg routinely produced by antihypertensive drugs.

Magnesium. Meta-analyses show modest systolic reductions, on the order of 3 mmHg, somewhat greater in hypertension and at higher doses. (14) The effect is real but small; in patients on optimized regimens, additive lowering can occasionally cause dizziness or orthostatic symptoms. This is worth noting to a prescriber rather than a reason to avoid magnesium.

Dietary nitrate and beetroot. A meta-analysis found systolic reductions of about 4 mmHg, with no significant diastolic effect. (15) The more important interaction is specific: combining nitrate-containing supplements with nitrate medications — sublingual nitroglycerin, isosorbide mononitrate or dinitrate — or with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) can produce additive nitric-oxide signaling and severe hypotension. That is a combination to avoid, not merely monitor.

L-arginine and L-citrulline. Nitric-oxide precursors with modest blood-pressure effects (around 5/3 mmHg with L-arginine in meta-analysis), additive with antihypertensives. (16) The safety signal for L-arginine in established cardiovascular disease — discussed in Article 12 — adds a separate, L-arginine-specific concern.

CoQ10. Some meta-analyses show a modest reduction; effects are smaller and less consistent in more recent trials. (17) Disclosure is appropriate; urgency is low.

Monitoring blood pressure when starting any supplement with potential antihypertensive effect is the practical safeguard. Symptoms of excessive lowering include dizziness on standing, lightheadedness, fatigue, and fainting.

Blood Sugar: Additive Hypoglycemia Risk

Patients on insulin or sulfonylureas already carry meaningful hypoglycemia risk from their medications, and supplements with glucose-lowering effects add to it in ways that are not always anticipated. Berberine — the most significant concern in this setting — lowers glucose to a degree that approaches metformin in some small trials, so combining it with insulin or a sulfonylurea makes additive hypoglycemia a genuine concern; if it is being considered, the prescriber needs to know and glucose monitoring should increase during initiation. Alpha-lipoic acid may improve insulin sensitivity at higher doses, a weaker signal than berberine but still relevant in insulin-dependent patients. Chromium and cinnamon have small, inconsistent glucose effects, where the interaction is largely theoretical at the magnitudes documented. Knowing the symptoms of hypoglycemia — shakiness, sweating, rapid heart rate, confusion, blurred vision, hunger — and increasing self-monitoring for the first few weeks after adding any glucose-affecting supplement is the practical safeguard.

Statin-Specific Interactions: Myopathy Risk

Statins are among the most important cardiovascular medications, and their interaction with supplements that raise statin blood levels — through CYP3A4 inhibition — is one of the most clinically relevant categories for cardiovascular patients. The statin matters: simvastatin and lovastatin are most sensitive to CYP3A4 interactions, atorvastatin somewhat less, while pravastatin, rosuvastatin, and fluvastatin use different pathways and are substantially less affected. (13) Berberine raises levels of simvastatin, lovastatin, and atorvastatin through CYP3A4 inhibition, increasing myopathy risk with no added LDL benefit; where berberine is used for metabolic reasons in a statin patient, switching to a less CYP3A4-dependent statin is a decision for the prescriber. (3) Red yeast rice adds unregulated statin exposure on top of a prescription statin. (4) Grapefruit raises simvastatin and lovastatin levels several-fold. (13) The warning signs that call for medical evaluation are new or unexplained muscle pain, weakness, or cramping in a statin patient — particularly after starting a new supplement — and dark or cola-colored urine, which suggests rhabdomyolysis (severe muscle breakdown that can cause acute kidney failure) and is a medical emergency.

Two Patients, Same Medication Aisle, Different Answers

Both profiles below are composites built from documented interaction patterns described in the pharmacovigilance literature.

Patient A is a 72-year-old man with atrial fibrillation on warfarin (INR target 2–3, stable for eighteen months), taking a daily multivitamin without issue. At his most recent check, his INR was 1.5 — below range for the first time in over a year. Asked about new products, he mentions starting St. John’s Wort six weeks ago for low mood after his wife’s death.

The clinical work here is recognizing the connection. St. John’s Wort induces CYP2C9, the enzyme that metabolizes warfarin’s active form, lowering warfarin levels and anticoagulation. (1,9) His INR drop matches the mechanism and the timeline matches the typical onset. The course his clinicians would weigh is discontinuing the St. John’s Wort, rechecking the INR within a week, and discussing alternative treatments for his depression that do not interact with warfarin. The stakes are why it matters: a subtherapeutic INR in atrial fibrillation raises stroke risk, and a stroke from a missed interaction is exactly the harm this article exists to prevent. He had no idea St. John’s Wort could affect his warfarin — few patients do.

Patient B is a 68-year-old woman with heart failure (ejection fraction 35%) and chronic kidney disease (eGFR 42), on lisinopril, metoprolol, furosemide, and spironolactone. Having read that potassium is good for the heart, she began using a potassium-based salt substitute liberally in cooking plus a daily 99 mg potassium supplement. She comes in feeling more fatigued than usual with occasional palpitations; her serum potassium is 6.2 mEq/L (target below 5.0) and her ECG shows peaked T waves.

This is the most dangerous combination in the article and among the most preventable causes of life-threatening hyperkalemia. She is on two medications that reduce potassium excretion (lisinopril and spironolactone), she has chronic kidney disease that further impairs it, and she is adding potassium from two sources. Each element is reasonable in isolation; together they are dangerous. The course her clinical team would weigh is urgent evaluation for hyperkalemia, immediate cessation of both potassium sources, careful review of her cardiac medications by cardiology, and a clear monitoring and dietary plan going forward. The interventions protecting her heart — the ACE inhibitor and spironolactone — are also contributing to the hyperkalemia, which is why this requires medical management rather than simply stopping a medication. Her supplement decisions were reasonable in isolation; combined with her medications and kidney function, they were not.

Common Misconceptions

“My supplements don’t matter to my heart doctor — they’re not medications.” Pharmacologically, they are. The supplements in this article alter drug metabolism, clotting, electrolyte handling, blood pressure, or blood glucose. The legal classification as “supplement” rather than “drug” does not change the chemistry.

“If a supplement is sold without a prescription, the FDA must have confirmed it’s safe with my medications.” It has not. The FDA does not pre-approve dietary supplements for safety or efficacy, and manufacturers are not required to test for drug interactions. Many interactions in this article emerged from case reports and post-marketing surveillance years after a supplement was in wide use.

“Natural supplements can’t have serious drug interactions.” Several do. St. John’s Wort is one of the most widely-acting supplement–drug interactors in clinical pharmacology. (1) Vitamin K supplements can render warfarin ineffective. Potassium supplements can cause life-threatening hyperkalemia in patients on ACE inhibitors with kidney disease. (2) Berberine inhibits multiple CYP450 enzymes at clinically relevant levels. (3) “Natural” is a marketing term, not a pharmacological one.

“If I’ve taken the supplement for years without problems, I don’t need to mention it now.” Interactions can emerge when medications change. Adding a statin, switching from warfarin to a DOAC, or starting an antiarrhythmic can convert a previously inert supplement into an active interactor. Disclosure is for the current regimen, not just the original one.

“Standard fish oil thins my blood, so I should stop it before any procedure.” Standard over-the-counter fish oil at 1–3 grams daily has not been shown to cause clinically significant bleeding. (11) The bleeding signal is real for prescription icosapent ethyl at 4 grams daily but borderline for serious bleeding and limited to that dose and formulation. (12) Stopping standard fish oil before a procedure may be reasonable on caution grounds, but the evidence for routine pre-operative discontinuation is weaker than commonly stated — a question for the surgeon and prescriber.

“Combining several ‘heart healthy’ supplements must help more.” Combining supplements compounds interaction risk without compounding benefit. A patient taking ginkgo, garlic, fish oil, vitamin E, and CoQ10 alongside warfarin has stacked several potential warfarin-affecting compounds; each interaction may be modest, but the cumulative risk is not.

“My pharmacist can’t help with supplements because they aren’t drugs.” Pharmacists are the most accessible and specifically trained resource for interaction screening. Most pharmacies can evaluate a supplement–drug combination from the label or ingredient list. It is a free resource that is systematically underused.

Why Predicting Interactions Is Harder Than Any List Suggests

Everything above — the tiers, the mechanisms, the medication-by-medication detail — assumes a supplement contains what its label claims, in a consistent dose, without contaminants. That assumption is weaker than it sounds, which is part of why no article can be a complete or final guide.

Supplement contents are not always standardized: independent testing has documented products whose contents diverge from their labels in active ingredient, dose, or undeclared additions. Contaminants and adulteration with undeclared pharmaceuticals have been reported across multiple categories. Most botanical supplements contain dozens of bioactive compounds, not the single named one, while most mechanism studies use purified compounds — the bottle on the shelf is not that purified preparation. Batch-to-batch variability is substantial: monacolin K in commercial red yeast rice varies roughly 100-fold across identically labeled products, and similar variability affects most botanicals. (4) And individual response varies with CYP enzyme genetics, gut microbiome, age, kidney function, and concurrent medications.

What this article can do is identify which interactions to suspect and which categories of risk apply. What it cannot do — what nothing can do from mechanism alone — is predict precisely how much a specific product will affect a specific medication in a specific person, or guarantee that a supplement not discussed here is therefore safe. That gap is filled by ongoing pharmacist and prescriber involvement, by monitoring, and by a willingness to stop or adjust when something appears to be changing.

The Bottom Line

Supplements are biologically active. They affect enzymes, receptors, clotting pathways, electrolyte handling, and glucose metabolism in ways that overlap directly with what cardiovascular medications do. The label on the bottle does not change the chemistry in the bloodstream. Three principles apply across everything covered here.

Disclose everything. Every supplement, every prescriber, every visit — as ongoing practice, not a one-time event. Supplements change, medications change, and the interaction landscape changes with them. This is the single step that converts a hidden risk into a managed one.

Understand the hierarchy. St. John’s Wort with cardiovascular drugs, vitamin K supplements with warfarin, potassium supplements with ACE inhibitors or ARBs in kidney disease, berberine with statins or anticoagulants, and red yeast rice combined with a prescription statin are the interactions most likely to cause serious harm. (1,2,3,4) The rest warrant attention without alarm.

Mechanism flags risk; the supplement adds uncertainty. The category of interaction is usually predictable: a supplement that affects clotting raises bleeding concerns with anticoagulants; one that slows liver drug processing raises drug-level concerns for medications cleared by that pathway. But predicting magnitude from mechanism assumes a supplement contains what its label claims, in a consistent dose, without contaminants — assumptions the marketplace does not reliably support. Mechanism tells you which interactions to suspect; monitoring tells you what is happening.

A closing reminder on scope: this article covers selected, well-documented interactions, not all of them. The absence of a supplement here is not evidence that it is safe to combine with your medications — it means the question was not addressed and belongs with your prescriber or pharmacist. The relevant question is never whether a supplement is safe in isolation; it is whether it changes the same biological systems your medications depend on, and whether that change moves your risk in a direction that matters.

This concludes Cardiovascular Supplements: An Evidence-Based Guide. The tools built across the series — the Ten Questions from Article 1, the two-question framework from Article 2, the Outcomes Ladder from Article 3, and this interaction framework — apply to whatever supplement comes next, including the many this series never named.

Key Terms

ACE inhibitor: A medication that blocks angiotensin-converting enzyme, lowering blood pressure and cardiac workload. Also reduces potassium excretion, creating hyperkalemia risk with potassium supplements.

ARB (angiotensin receptor blocker): A medication that blocks the angiotensin II receptor; similar to ACE inhibitors for blood pressure and potassium retention.

CYP3A4: The most important cytochrome P450 enzyme in drug metabolism, processing roughly half of all prescription medications. Inhibited by berberine and grapefruit; induced by St. John’s Wort.

DOAC (direct oral anticoagulant): Apixaban, rivaroxaban, dabigatran, edoxaban — blood thinners that act by direct factor inhibition rather than vitamin K interference. Not affected by dietary vitamin K but susceptible to CYP3A4 and P-glycoprotein interactions.

Hyperkalemia: Dangerously elevated blood potassium (above roughly 5.0–5.5 mEq/L depending on context). Can cause life-threatening arrhythmias; risk amplified by kidney disease and medications that reduce potassium excretion.

INR (International Normalized Ratio): The standardized measure of anticoagulation in warfarin-treated patients. Interactions that raise INR increase bleeding risk; those that lower it increase clotting risk.

P-glycoprotein: A transporter that pumps drugs out of cells, limiting absorption. Inhibited by berberine; induced by St. John’s Wort. Affects several DOACs and other cardiovascular drugs.

Rhabdomyolysis: Severe skeletal-muscle breakdown releasing myoglobin into the blood, potentially causing acute kidney failure. A rare but serious statin effect whose risk rises when statin levels are elevated by CYP3A4 inhibitors. Warning signs: severe muscle pain and weakness, dark or cola-colored urine. A medical emergency.

St. John’s Wort (Hypericum perforatum): A herbal supplement used for depression and the broadest supplement–drug interactor in common use, inducing multiple drug-processing pathways and reducing levels of statins, warfarin, DOACs, calcium channel blockers, and other cardiovascular drugs.

Therapeutic window: The range of drug concentration between the minimum effective level and the level at which toxicity occurs. Narrow-window drugs — warfarin, digoxin, certain antiarrhythmics — are the most susceptible to clinically significant interactions.

References

1. Nicolussi S, Drewe J, Butterweck V, Meyer zu Schwabedissen HE. Clinical relevance of St. John’s wort drug interactions revisited. Br J Pharmacol. 2020;177(6):1212–1226.
2. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f1378.
3. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213–217.
4. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170(19):1722–1727.
5. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000;57(13):1221–1227.
6. Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with Ginkgo biloba: a case report and systematic review of the literature. J Gen Intern Med. 2005;20(7):657–661.
7. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46.
8. Weng Y, Yao J, Sparks S, Wang KY. Nattokinase: an oral antithrombotic agent for the prevention of cardiovascular disease. Int J Mol Sci. 2017;18(3):523.
9. Yue QY, Bergquist C, Gerdén B. Safety of St John’s wort (Hypericum perforatum). Lancet. 2000;355(9203):576–577.
10. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777–1798.
11. Javaid M, Kadhim K, Bawamia B, Cartlidge T, Farag M, Alkhalil M. Bleeding risk in patients receiving omega-3 polyunsaturated fatty acids: a systematic review and meta-analysis of randomized clinical trials. J Am Heart Assoc. 2024;13(10):e032390.
12. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. (REDUCE-IT)
13. Bailey DG, Dresser G, Arnold JMO. Grapefruit–medication interactions: forbidden fruit or avoidable consequences? CMAJ. 2013;185(4):309–316.
14. Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr. 2012;66(4):411–418.
15. Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr. 2013;143(6):818–826.
16. Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011;162(6):959–965.
17. Rosenfeldt FL, Haas SJ, Krum H, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21(4):297–306.

HeartBuddi • Your heart. Own it. • This article is part of an evidence-based educational series and is not a substitute for individualized medical advice. It describes selected interactions only and is not a complete account of how any supplement may interact with your medications.